Stockreport

Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline [Yahoo! Finance]

Ocugen, Inc.  (OCGN) 
PDF Quick Read Ocugen (OCGN) completed enrollment of 140 patients in its Phase 3 retinitis pigmentosa trial for OCU400, with topline data expected in Q1 2027 and a rollin [Read more]